Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery
JAMA Network Open · 11.03.2026 · 9 (3) · e260390
DOI: 10.1001/jamanetworkopen.2026.0390 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 11.03.2026. Verfasst von Tuo Pan und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Glycine, Respiratory Distress Syndrome, Postoperative Complications, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Acute respiratory distress syndrome (ARDS) represents a frequent and serious complication after cardiovascular surgery. Although sivelestat, a specific neutrophil elastase inhibitor, has demonstrated therapeutic potential in preliminary studies, the evidence remains limited by methodological constraints of observational designs and underpowered studies.
Objective
To evaluate the efficacy of sivelestat vs placebo in reducing the incidence of postoperative ARDS and associated complications among patients undergoing major cardiovascular procedures. Design, Setting, and Participants This single-center, randomized, placebo-controlled clinical trial conducted at a tertiary care academic medical center om China enrolled 424 participants between February 15, 2024, and April 16, 2025, with a 90-day postoperative follow-up period. Participants were consecutive patients scheduled for cardiovascular surgery, including coronary artery bypass grafting, valve surgeries, ascending aortic reconstruction, combined procedures, congenital heart defect repairs, and cardiac tumor resections.
Interventions
Participants were randomly allocated (1:1) to receive either continuous intravenous sivelestat (0.2 mg/kg/h), initiated immediately on intensive care unit (ICU) admission postoperatively and continued for up to 7 days or until ICU discharge; or volume-matched 0.9% sodium chloride placebo administered on an identical schedule. Main Outcomes and Measures The primary outcome was the incidence of ARDS. Secondary outcomes included serial measurements of inflammatory biomarkers, including interleukin 6 and interleukin 8, tumor necrosis factor, systemic immune-inflammation index, and serum neutrophil elastase, on postoperative days 1, 3, 5, and 7, along with ARDS-related clinical outcomes including death, pneumonia, and reintubation. Analysis was performed on an intention-to-treat basis.
Results
Among 424 randomized patients, 382 completed the trial (mean [SD] age, 62.9 [6.2] years; 210 male [55.0%]). Adverse events monitored for safety did not differ between groups. The sivelestat group had significantly lower rates of ARDS (16.8% [32 of 190] vs 31.2% [60 of 192]; P < .001), and 90-day mortality (1.1% [2 of 190] vs 5.2% [10 of 192]; P = .02). Postoperative inflammatory biomarkers, including neutrophil elastase and interleukin 6, were significantly reduced in the sivelestat group. Conclusion and Relevance In this single-center, randomized, placebo-controlled clinical trial of patients undergoing cardiovascular surgery, sivelestat significantly reduced ARDS incidence and 90-day all-cause mortality. Sivelestat attenuated neutrophil-driven inflammation by dynamically suppressing neutrophil elastase and reducing key downstream biomarkers. These preliminary findings suggest sivelestat may be a pharmacologic option to mitigate ARDS in cardiovascular procedures. Trial Registration ClinicalTrials.gov Identifier: NCT06276569
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Division of Cardiac Anesthesia, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei City, Anhui Province, China.
- Department of Cardiac Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Cardiac Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huai'an, Jiangsu, China.
Zitieren
APA
Pan, T., Xu, C., Wang, Y. P., Wang, H. L., Su, W. X., Zhang, H. T., Zhu, E. J., Li, Y. T., Lv, Z. K., Zhu, T. T., Xu, Z. W., Gao, Y., Xu, C. Z., Shi, J., Ji, W. J., Duan, Z. H., Zhang, C., Xu, Z. J., Li, K. S., …, & Wang, Q. (2026). Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery. JAMA Network Open, 9(3), e260390. https://doi.org/10.1001/jamanetworkopen.2026.0390
Vancouver
Pan T, Xu C, Wang YP, Wang HL, Su WX, Zhang HT, et al. Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery. JAMA Network Open. 2026;9(3):e260390. doi:10.1001/jamanetworkopen.2026.0390
BibTeX
@article{Pan2026,
author = {Pan, Tuo and Xu, Can and Wang, Ya-Peng and Wang, Hui-Li and Su, Wen-Xin and Zhang, Hai-Tao and Zhu, Er-Jun and Li, Yong-Tao and Lv, Zhi-Kang and Zhu, Tong-Tong and Xu, Zhi-Wei and Gao, Yang and Xu, Chuan-Zhang and Shi, Jian and Ji, Wen-Jie and Duan, Ze-Hua and Zhang, Cheng and Xu, Zhen-Jun and Li, Kun-Sheng and Chong, Hoshun and Zhu, Xi-Yu and Xue, Yun-Xing and Xu, Wan-Zi and Chen, Cheng and Zhao, Wei-Wei and Ye, Jia-Xin and Ge, Min and Xu, Gao-Jun and Wu, Shu-Min and Pan, Jun and Wang, Dong-Jin and Qu, Jason Z and Wang, Qiang},
title = {Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {3},
pages = {e260390},
doi = {10.1001/jamanetworkopen.2026.0390}
}
EUVIMED